LeMaitre (LMAT) To Report Earnings Tomorrow: Here Is What To Expect
LeMaitre (LMAT) To Report Earnings Tomorrow: Here Is What To Expect
Radek Strnad
Tue, February 24, 2026 at 12:19 PM GMT+9 2 min read
In this article:
LMAT
-1.68%
Medical device company LeMaitre Vascular (NASDAQ:LMAT) will be announcing earnings results this Wednesday after market hours. Here’s what to expect.
LeMaitre missed analysts’ revenue expectations last quarter, reporting revenues of $61.05 million, up 11.4% year on year. It was a mixed quarter for the company, with a beat of analysts’ EPS estimates but revenue guidance for next quarter missing analysts’ expectations significantly.
Is LeMaitre a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting LeMaitre’s revenue to grow 12.9% year on year, slowing from the 14% increase it recorded in the same quarter last year.
LeMaitre Total Revenue
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. LeMaitre has missed Wall Street’s revenue estimates multiple times over the last two years.
Looking at LeMaitre’s peers in the healthcare equipment and supplies segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Intuitive Surgical delivered year-on-year revenue growth of 18.8%, beating analysts’ expectations by 1%, and Envista reported revenues up 15%, topping estimates by 10.6%. Intuitive Surgical’s stock price was unchanged after the resultswhile Envista was up 17.8%.
Read our full analysis of Intuitive Surgical’s results here and Envista’s results here.
The outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.5% on average over the last month. LeMaitre is up 7.2% during the same time and is heading into earnings with an average analyst price target of $103.67 (compared to the current share price of $91.40).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
Terms and Privacy Policy
Privacy Dashboard
More Info
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
LeMaitre (LMAT) To Report Earnings Tomorrow: Here Is What To Expect
LeMaitre (LMAT) To Report Earnings Tomorrow: Here Is What To Expect
LeMaitre (LMAT) To Report Earnings Tomorrow: Here Is What To Expect
Radek Strnad
Tue, February 24, 2026 at 12:19 PM GMT+9 2 min read
In this article:
LMAT
-1.68%
Medical device company LeMaitre Vascular (NASDAQ:LMAT) will be announcing earnings results this Wednesday after market hours. Here’s what to expect.
LeMaitre missed analysts’ revenue expectations last quarter, reporting revenues of $61.05 million, up 11.4% year on year. It was a mixed quarter for the company, with a beat of analysts’ EPS estimates but revenue guidance for next quarter missing analysts’ expectations significantly.
Is LeMaitre a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting LeMaitre’s revenue to grow 12.9% year on year, slowing from the 14% increase it recorded in the same quarter last year.
LeMaitre Total Revenue
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. LeMaitre has missed Wall Street’s revenue estimates multiple times over the last two years.
Looking at LeMaitre’s peers in the healthcare equipment and supplies segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Intuitive Surgical delivered year-on-year revenue growth of 18.8%, beating analysts’ expectations by 1%, and Envista reported revenues up 15%, topping estimates by 10.6%. Intuitive Surgical’s stock price was unchanged after the resultswhile Envista was up 17.8%.
Read our full analysis of Intuitive Surgical’s results here and Envista’s results here.
The outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.5% on average over the last month. LeMaitre is up 7.2% during the same time and is heading into earnings with an average analyst price target of $103.67 (compared to the current share price of $91.40).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
Terms and Privacy Policy
Privacy Dashboard
More Info